Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Unverricht-Lundborg syndrome
- Focus Registrational; Therapeutic Use
- Sponsors UCB
- 15 Dec 2015 Results from this and other trial (see profile 16138) published in the Epilepsia
- 19 Dec 2007 New trial record.
- 14 Dec 2007 Full results of the analysis of secondary endpoints are expected by the second quarter of 2008.